Follow The Filings

NRIX Nurix Therapeutics

Nurix Therapeutics earnings company data as of 7:13 AM ET 10/13

  • 0 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 8 Oct EPS 5.11 4.73 Miss -7.5%
Rev $479.5M $673.1M Beat +40.4%

Insider trades

Open-market buys and sales by NRIX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NRIX insider trades
  • None no insider bought on the open market
  • $529K sold by 1 insider outside a trading plan
  • $4M sold by 3 insiders under 10b5-1 plans
  1. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $36K 1,452 shares at $25.00 1.2% of stake
    Traded Oct 15 Filed Oct 15
    ↗
  2. Julia P Gregory Director
    Sale
    $529K 22,583 shares at $23.40 68% of stake
    Traded Oct 14 Filed Oct 14
    ↗
  3. Christine Ring Chief Legal Officer
    Planned sale
    $134K 5,786 shares at $23.19 39% of stake
    Traded Oct 2 Filed Oct 2
    ↗
  4. Christine Ring Chief Legal Officer
    Planned sale
    $149K 5,787 shares at $25.76 39% of stake
    Traded Sep 2 Filed Sep 2
    ↗
  5. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $37K 1,452 shares at $25.47 1.2% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  6. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $109K 4,356 shares at $25.00 3.6% of stake
    Traded Aug 5 Filed Aug 5
    ↗
  7. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $100K 4,111 shares at $24.36 3.4% of stake
    Traded Aug 4 Filed Aug 5
    ↗
  8. Hans Van Houte CFO
    Planned sale
    $116K 4,761 shares at $24.36 11% of stake
    Traded Aug 4 Filed Aug 4
    ↗
  9. Christine Ring Chief Legal Officer
    Planned sale
    $382K 16,589 shares at $23.05 65% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  10. Christine Ring Chief Legal Officer
    Planned sale
    $259K 11,008 shares at $23.56 45% of stake
    Traded Jul 2 Filed Jul 2
    ↗
  11. Christine Ring Chief Legal Officer
    Planned sale
    $581K 28,935 shares at $20.06 68% of stake
    Traded Jun 25 Filed Jun 25
    ↗
  12. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $108K 5,394 shares at $20.00 4.5% of stake
    Traded Jun 25 Filed Jun 25
    ↗
  13. Christine Ring Chief Legal Officer
    Planned sale
    $135K 8,148 shares at $16.60 38% of stake
    Traded Jun 2 Filed Jun 2
    ↗
  14. Hans Van Houte CFO
    Planned sale
    $233K 14,055 shares at $16.60 27% of stake
    Traded May 5 Filed May 5
    ↗
  15. Christine Ring Chief Legal Officer
    Planned sale
    $138K 8,148 shares at $16.96 31% of stake
    Traded May 4 Filed May 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 58 option exercises and 15 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.